The Breast and Gynecologic Cancer Research Group conducts and fosters the development of research on the prevention and early detection of breast cancer, cervix and human papillomavirus (HPV)-related cancers, endometrial cancers, ovarian cancers, and precursor conditions related to these cancers.
Cancer Prevention Clinical Trials Network (CP-CTNet)
Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.
Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
Major medical research centers conduct systematic early clinical development of promising preventive agents.
US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)
Partnership Centers will focus on improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals.
The ASCUS/LSIL Triage Study for Cervical Cancer (ALTS)
ALTS was a clinical trial to find the best way to help women and their doctors decide what to do about the mildly abnormal and very common Pap test results known as ASCUS and LSIL.
Addressing a ‘Last Mile’ Problem in Cervical Cancer Screening
A presentation (PDF, 1.12 MB) from the 14th Joint Meeting of the NCI Board of Scientific Advisors (BSA) and the National Cancer Advisory Board (NCAB) - December 2-3, 2019 by Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Study Seeks to Prevent Cancer and Extend Quality of Life for Women at Increased Genetic Risk of Ovarian Cancer
Researchers in gynecologic oncology have begun testing a promising surgery for premenopausal women at high genetic risk for ovarian cancer that avoids early menopause and may prevent these malignancies from developing.
Making Informed Choices on Incorporating Chemoprevention Into Breast Care: Q & A with Dr. Katherine Crew on the MiCHOICE Trial
The SWOG Cancer Research Network is opening to accrual the MiCHOICE Trial to study the use of decision support tools by women with high-risk breast conditions and their healthcare providers to choose among chemoprevention options. The MiCHOICE Trial was previously mentioned in the November 19 Cancer Prevention Science blog post How Patients and Their Doctors Determine Cancer Risk—and What...
How Patients and Their Doctors Determine Cancer Risk—and What Happens Next
If you were concerned that you might be at increased risk for a specific kind of cancer, what would you do to confirm that risk, and what would you be willing to do to reduce that risk? The answer is likely to be, "it depends on your doctor."
Projects Making Progress in Breast Cancer Detection and Prevention, By: Philip E. Castle
In the month of October, breast cancer awareness is the health message that looms large. Yet, researchers across the National Cancer Institute and across the world are focused on breast cancer all the time. In the United States, more than 275,000 women are expected to be diagnosed with breast cancer this year and more than 3.5 million are breast cancer survivors.
Research Issues in Gynecology and Women's Health: How do Benign Conditions Become Cancer?
Research to uncover how and why benign gynecologic conditions like endometriosis or uterine fibroids progress to invasive and deadly ovarian cancer or uterine sarcomas, is a critical and overlooked issue in women’s health. A new report on research priorities and an open funding opportunity are focused on addressing this issue.